This archive contains links to the full-text of all issues of Clin Mol Hepatol.
First decision
09 Days
Publication after acceptance
04 Days
*Last 12 months
Viewed By 5203 |
MAFLD: How is it different from NAFLD? |
Viewed By 5182 |
Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma |
Viewed By 4295 |
Recent advances in the management of hepatocellular carcinoma |
Viewed By 3499 |
Global incidence and prevalence of nonalcoholic fatty liver disease |
Viewed By 3001 |
Management of refractory ascites |
Cited By 104 |
Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma |
Cited By 99 |
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma |
Cited By 64 |
Global incidence and prevalence of nonalcoholic fatty liver disease |
Cited By 59 |
Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach |
Cited By 49 |
MAFLD enhances clinical practice for liver disease in the Asia-Pacific region |